Prestige Biopharma has taken an increased and controlling stake in its Prestige Biologics contract development and manufacturing organization, at the same time as announcing that Duk-Hoon Hyun had been appointed as the unit’s new CEO.
Commenting on the increased shareholding in Prestige Biologics, Prestige Biopharma indicated that it would “become the largest shareholder of Prestige Biologics by acquiring new shares to secure a total of 24.88% of the CDMO company
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?